Idioma:

Incidence of adverse effects in patients receiving ponatinib with concomitant azole antifungals

Marx, Kayleigh R. ; Rausch, Caitlin R. ; Lovell, Alexandra R. ; Short, Nicholas J. ; Paul, Shilpa ; Jain, Nitin ; Lee, Jenessa ; Savoy, J. Michael ; Ravandi, Farhad ; Jabbour, Elias

Leukemia & lymphoma, 2023-01, Vol.64 (1), p.79-86 [Periódico revisado por pares]

United States: Taylor & Francis

Texto completo disponível

Citações Citado por

Enviar para

Título:
Incidence of adverse effects in patients receiving ponatinib with concomitant azole antifungals
Autor: Marx, Kayleigh R. ; Rausch, Caitlin R. ; Lovell, Alexandra R. ; Short, Nicholas J. ; Paul, Shilpa ; Jain, Nitin ; Lee, Jenessa ; Savoy, J. Michael ; Ravandi, Farhad ; Jabbour, Elias
Assuntos: Antifungal Agents - adverse effects ; Drug-Related Side Effects and Adverse Reactions ; Humans ; Imidazoles - adverse effects ; Incidence ; Philadelphia Chromosome ; Ponatinib ; ponatinib adverse events ; ponatinib and azoles ; Protein Kinase Inhibitors - therapeutic use ; Pyridazines - adverse effects
É parte de: Leukemia & lymphoma, 2023-01, Vol.64 (1), p.79-86
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição: Ponatinib plus Hyper-CVAD yields a five-year overall survival of 73% in patients with Philadelphia-positive acute lymphoblastic leukemia. Ponatinib dose intensity is associated with increased incidence of adverse effects (AEs), including vascular events. Ponatinib combined with azole antifungals may further increase the risk of AEs due to increased ponatinib exposure. We reviewed 53 patients who received ponatinib with intensive (n = 39; 74%) or low-intensity chemotherapy (n = 14; 26%). Forty-eight patients (91%) received concomitant azole. Ponatinib was commonly initiated at 30 mg (n = 30; 57%) or 45 mg daily (n = 21; 40%). Twenty-six patients (49%) experienced at least one grade ≥3 AE possibly related to ponatinib; 19 (73%) were receiving a ponatinib dose equivalent ≥30mg and 58% >45mg. Eight patients (15%) experienced 10 vascular events, including 1 arterial event; 9 occurred on a ponatinib dose equivalent ≥30mg and 5 occurred while on an azole. Vascular events pose a clinical challenge with the risk potentially increasing with concomitant azoles.
Editor: United States: Taylor & Francis
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Incidence of adverse effects in patients receiving ponatinib with concomitant azole antifungals

Marx, Kayleigh R. ; Rausch, Caitlin R. ; Lovell, Alexandra R. ; Short, Nicholas J. ; Paul, Shilpa ; Jain, Nitin ; Lee, Jenessa ; Savoy, J. Michael ; Ravandi, Farhad ; Jabbour, Elias

United States: Taylor & Francis

Buscando em bases de dados remotas. Favor aguardar.